Consolidated Gems, Inc. Share Price

Equities

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-.--%

17/04	BTIG Adjusts Price Target on Cullinan Oncology to $30 From $20, Maintains Buy Rating	MT
16/04	HC Wainwright Cuts Cullinan Oncology's Price Target to $29 From $34, Maintains Buy Rating	MT

Duration

Period

Style

BTIG Adjusts Price Target on Cullinan Oncology to $30 From $20, Maintains Buy Rating	17/04	MT
HC Wainwright Cuts Cullinan Oncology's Price Target to $29 From $34, Maintains Buy Rating	16/04	MT
Wedbush Raises Cullinan Oncology Price Target to $36 From $30, Maintains Outperform Rating	16/04	MT
William Blair Initiates Cullinan Oncology With Outperform Rating	15/04	MT
Cullinan Oncology Finance Chief Jeffrey Trigilio to Leave	14/03	MT
Cullinan Oncology Secures FDA Approval for CLN-619's Investigational New Drug Application in Multiple Myeloma	01/03	MT
Wedbush Starts Cullinan Oncology With Outperform Rating, $30 Price Target	15/02	MT
Cullinan Oncology Insider Sold Shares Worth $647,200, According to a Recent SEC Filing	05/02	MT
Cullinan Oncology Insider Sold Shares Worth $563,600, According to a Recent SEC Filing	31/01	MT
Cullinan Oncology Doses First Patient in Study of Advanced Solid Tumor Treatment Candidate	15/12	MT
JonesTrading Initiates Cullinan Oncology With Buy Rating, Price Target is $22	06/23/06	MT
TD Cowen Starts Cullinan Oncology at Outperform	15/23/15	MT
Insider Sell: Cullinan Oncology	09/23/09	MT
HC Wainwright Adjusts Price Target on Cullinan Oncology to $49 From $50, Maintains Buy Rating	12/23/12	MT
Cullinan Oncology Gets FDA Clearance for CLN-617 Study	27/23/27	MT

BTIG Adjusts Price Target on Cullinan Oncology to $30 From $20, Maintains Buy Rating	17/04	MT
HC Wainwright Cuts Cullinan Oncology's Price Target to $29 From $34, Maintains Buy Rating	16/04	MT
Wedbush Raises Cullinan Oncology Price Target to $36 From $30, Maintains Outperform Rating	16/04	MT
William Blair Initiates Cullinan Oncology With Outperform Rating	15/04	MT
Wedbush Starts Cullinan Oncology With Outperform Rating, $30 Price Target	15/02	MT

Managers	Title	Age	Since
Mordechai Zev Gutnick CEO	Chief Executive Officer	47	-
Peter James Lee DFI	Director of Finance/CFO	66	01/08/01

Members of the board	Title	Age	Since
Mordechai Zev Gutnick CEO	Chief Executive Officer	47	-

Consolidated Gems Inc is an Australia-based company. The Company is a provider of business support services.

Sector

	1st Jan change	Capi.
CONSOLIDATED GEMS, INC.	-.--%	4M
IMPALA PLATINUM HOLDINGS LIMITED	-5.74%	4.11B
SINO-PLATINUM METALS CO.,LTD	+2.65%	1.55B
SILVERCREST METALS INC.	+33.83%	1.25B
A-MARK PRECIOUS METALS, INC.	+32.63%	917M
IMPALA CANADA LTD.	+82.85%	881M
HENAN HUANGHE WHIRLWIND CO., LTD.	-24.60%	561M
FURUYA METAL CO., LTD.	+12.36%	558M
PYX RESOURCES LIMITED	-.--%	153M
VOX ROYALTY CORP.	+5.45%	106M